TICKERNERD
Menu
CODXCODXHealthcare · Medical Devices

CODX Stock Forecast: Co-Diagnostics, Inc. Price Predictions for 2026-2027

Last close, 16 Oct 2026
$0.65
−8.53% on the day

The 1 Wall Street analysts covering Co-Diagnostics, Inc. hold a median 12-month price target of $4 — +511.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 16 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$5.0M
Ticker Nerd rank
38 / 100
Median analyst target
$4.00
Analysts covering
1
Revenue$166K+2.0% y/y
Operating income−$6.2M
Net income−$6.3M
Free cash flow−$7.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−41.6%
1M
−30.5%
YTD
−87.1%
1Y
−93.8%
From 52W high
−98.3%
From 52W low
0.0%
$1
$38
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CODX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Co-Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 16 Oct 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Size
95
Accruals
94
Revisions
46
Momentum
26
Issuance
16
Value
13
Quality
9
Volatility
8

Growth (99): Sales and profits are climbing, and climbing faster than before.

Volatility (8): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CODX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CODX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15Jan 26Apr 26Jul 26Oct 26CODXHigh $4.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $4.00Median $4.00High $4.00

The green dot is the last close — the median target sits +511.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Jan 2026Maxim GroupDowngradeHold—
26 Nov 2025Maxim GroupInitiatesBuy—
24 Nov 2025HC Wainwright & Co.ReiteratesNeutral—
28 Oct 2025D. Boral CapitalMaintainsBuy—
16 Oct 2025D. Boral CapitalMaintainsBuy—
19 Sept 2025D. Boral CapitalMaintainsBuy—
17 Sept 2025D. Boral CapitalMaintainsBuy—
15 Aug 2025D. Boral CapitalMaintainsBuy—
28 Apr 2025D. Boral CapitalInitiatesBuy—
28 Mar 2025HC Wainwright & Co.MaintainsNeutral—
11 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
12 Aug 2024HC Wainwright & Co.MaintainsNeutral—
17 June 2024HC Wainwright & Co.ReiteratesNeutral—
13 May 2024HC Wainwright & Co.MaintainsNeutral—
15 Mar 2024HC Wainwright & Co.MaintainsNeutral—
29 Dec 2023HC Wainwright & Co.ReiteratesNeutral—
13 Nov 2023HC Wainwright & Co.MaintainsNeutral—
14 Aug 2023HC Wainwright & Co.MaintainsNeutral—
15 May 2023HC Wainwright & Co.ReiteratesNeutral—
20 Mar 2023HC Wainwright & Co.DowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CODX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CODX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 16 Oct 2026, Co-Diagnostics, Inc. returned −93.8% against +16.8% for the S&P 500, dividends included.

CODX vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26CODXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CODX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Co-Diagnostics, Inc. (CODX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.0×

Cheaper than 76% of US stocks

Price / sales
6.9×

Cheaper than 18% of US stocks

Price / book
0.3×

Cheaper than 87% of US stocks

EV / EBITDA
−0.1×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
2.0%

Higher than 32% of US stocks

Earnings growth (YoY)
2.0%

Higher than 38% of US stocks

Gross margin
72.7%

Higher than 85% of US stocks

Operating margin
−3732.5%

Higher than 3% of US stocks

Net margin
64.3%

Higher than 97% of US stocks

Returns & dividend
Return on equity
−174.8%

Higher than 8% of US stocks

Return on assets
−59.6%

Higher than 6% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Co-Diagnostics, Inc. (CODX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Co-Diagnostics, Inc. has a market value of $5.0M and an enterprise value of $2.6M.

  • Revenue in the twelve months to 30 June 2026: $721K. The latest quarter grew 2.0% year on year.

  • Net income over the same four quarters: −$47.1M, a −6523.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$27.5M.

  • Shares outstanding: 4.9M.

  • Trailing P/E: −0.0×; forward P/E: −0.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Co-Diagnostics, Inc. employs 115 people — $6K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 16 Oct 2026

Data provided by Twelve Data

Peers

CODX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CODXCo-Diagnostics, Inc.$5.0M
38
WOKWORK Medical Technology Group Ltd.$4.9M
17
INBSIntelligent Bio Solutions, Inc.$5.0M
16
VNRXVolitionRX Ltd.$5.0M
42
NVNOenVVeno Medical Corp.$5.2M
26
VVOSVivos Therapeutics, Inc.$4.4M
36
AMIXAutonomix Medical, Inc.$5.6M
27

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Co-Diagnostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CODX news & analysis

Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection

PRNewsWire · 15 Oct 2026neutral

Co-Diagnostics said its Co-Dx PCR Pro point-of-care platform and existing sputum sample-preparation technology could provide a foundation for plague diagnostics if a public health need arises. The company is monitoring developments after the October 2 death of a laboratory worker at a plague research institute in Irkutsk, Russia.

Why it matters — The update highlights potential applications of CODX’s PCR platform and its rapid-response experience, but describes no current plague diagnostic test or deployment.

Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe

PRNewsWire · 8 Oct 2026positive

Co-Diagnostics received an order from the Ute Indian Tribe Mosquito Abatement Department for a full Vector Smart mosquito surveillance laboratory installation. It is the company’s first complete Vector Smart lab installation for a Native American tribe and will allow in-house PCR testing of mosquito pools.

Why it matters — The order marks a new installation milestone for Co-Diagnostics’ Vector Smart mosquito surveillance offering.

Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease

PRNewsWire · 7 Oct 2026positive

Co-Diagnostics highlighted momentum in its Vector Smart mosquito surveillance business after a federal executive order established an initiative to address mosquito- and tick-borne diseases through improved detection and related measures. The company also said it will participate in an October 9 Utah Global Health Leadership roundtable and four regional mosquito control conferences this fall.

Why it matters — The federal initiative and Co-Diagnostics’ planned industry appearances are relevant to watchers of its Vector Smart business and its positioning in mosquito surveillance.

Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development

PRNewsWire · 6 Oct 2026positive

Co-Diagnostics announced it will showcase the Co-Dx PCR platform and Co-Dx PCR MTB test at WHX Labs Johannesburg, October 6–8, 2026. The headline also highlights Ebola assay development for decentralized testing on the platform.

Why it matters — CODX watchers may note the company’s planned product showcase and Ebola assay development, though the excerpt provides no further details on the assay.

Co-Diagnostics to Participate in Global Health Events During UN General Assembly Week

PRNewsWire · 23 Sept 2026positive

Co-Diagnostics announced that Chief Commercialization Officer Seth Egan will represent the company at two global health events during the 81st Session of the UN General Assembly in New York City, including the UNOPS Hosted Partnerships Reception on September 23, 2026, which brings together global health leaders to examine tuberculosis and pandemic preparedness.

Why it matters — A CODX watcher would care because the company's participation alongside organizations like the Stop TB Partnership could raise its profile among global health leaders in areas relevant to its molecular diagnostic platform.

FAQ

Frequently asked questions about CODX stock

What is the CODX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Co-Diagnostics, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CODX stock a buy right now?

Of the 1 analysts covering Co-Diagnostics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Co-Diagnostics, Inc. 38 out of 100 across roughly 4,600 US stocks as at 16 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CODX?

As at 16 Oct 2026, Co-Diagnostics, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will CODX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +511.6% from the last close, and Ticker Nerd's factor model ranks Co-Diagnostics, Inc. 38 out of 100 as at 16 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CODX stock forecast for 2030?

No analyst covering Co-Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CODX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has CODX stock performed over the past year?

Co-Diagnostics, Inc. returned -93.8% over the 12 months to 16 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Co-Diagnostics, Inc. do?

Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets nucleic acid-based testing technologies for infectious disease detection and related applications.

What is the latest news on CODX?

The most recent item we track (PRNewsWire, 15 Oct 2026): "Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection". Co-Diagnostics said its Co-Dx PCR Pro point-of-care platform and existing sputum sample-preparation technology could provide a foundation for plague diagnostics if a public health need arises. The company is monitoring developments after the October 2 death of a laboratory worker at a plague research institute in Irkutsk, Russia.

Company

About Co-Diagnostics, Inc.

Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets nucleic acid-based testing technologies for infectious disease detection and related applications. Co-Diagnostics focuses on PCR-based solutions, including the Co-Dx PCR platform for point-of-care and at-home testing, as well as diagnostic tests for conditions such as COVID-19, influenza, tuberculosis, hepatitis, malaria, dengue, and other pathogens. The company also develops molecular tools for mosquito testing, agricultural pathogen detection, and genetic analysis in plant and animal genomes. Its proprietary Co-Primers technology is designed to support highly specific test development and simplify complex molecular testing workflows. Headquartered in Salt Lake City, Utah, Co-Diagnostics serves healthcare, public health, research, and agricultural markets through its diagnostics products and development platforms.

CEO Mr. Dwight H. Egan · 115 employees · United States · https://co-dx.com